 Connection
Rohit Katial to Severity of Illness Index
This is a "connection" page, showing publications Rohit Katial has written about Severity of Illness Index.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.844 |
|
|
|
-
Erekosima NU, Katial RK. Assessing nasal symptom control. Curr Allergy Asthma Rep. 2009 Mar; 9(2):134-9.
Score: 0.177
-
Xu X, Kwiatek J, Siddall J, Genofre E, Stirnadel-Farrant H, Katial R. Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice. BMC Gastroenterol. 2024 Aug 03; 24(1):246.
Score: 0.129
-
Katial RK, Hoyte FCL. Comment on geographic variation in disease burden among patients with severe persistent asthma in the United States. Ann Allergy Asthma Immunol. 2024 05; 132(5):551-552.
Score: 0.126
-
Katial JM, Hoyte FCL, Khatiwada A, Katial RK. Allergen skin test responses in broad U.S. asthma population in those with and without rhinitis. Allergy Asthma Proc. 2024 May 01; 45(3):158-165.
Score: 0.126
-
Fountain CR, Mudd PA, Ramakrishnan VR, Sillau SH, Kingdom TT, Katial RK. Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps. Ann Allergy Asthma Immunol. 2013 Nov; 111(5):337-41.
Score: 0.060
-
Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fager?s M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtim?ki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taill? C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von B?low A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024 Oct 01; 210(7):869-880.
Score: 0.033
-
Scelo G, Tran TN, Le TT, Fager?s M, Dorscheid D, Busby J, Al-Ahmad M, Al-Lehebi R, Altraja A, Beastall A, Bergeron C, Bjermer L, Bjerrum AS, Cano-Rosales DJ, Canonica GW, Carter V, Charriot J, Christoff GC, Cosio BG, Denton E, Fernandez-Sanchez MJ, Fonseca JA, Gibson PG, Goh C, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann D, Lehtim?ki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Patel P, Perez-De-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sadatsafavi M, Taill? C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von B?low A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2347-2361.
Score: 0.032
-
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ. Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary. Immunotherapy. 2024; 16(10):641-648.
Score: 0.032
-
Li X, Newbold P, Katial R, Hirsch I, Li H, Martin UJ, Meyers DA, Bleecker ER. Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness. J Allergy Clin Immunol Pract. 2024 Oct; 12(10):2732-2743.
Score: 0.032
-
Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M, Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Lawkiedraj A, Lehtim?ki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodr?guez-C?ceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, M?spero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taill? C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jim?nez-Maldonado L, Taube C, Brussino L, Price DB. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024; 15:1361891.
Score: 0.032
-
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ. Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial. J Eur Acad Dermatol Venereol. 2023 10; 37(10):e1211-e1214.
Score: 0.030
-
Chipps BE, Corren J, Israel E, Katial R, Lang DM, Panettieri RA, Peters SP, Farrar JR. Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. Ann Allergy Asthma Immunol. 2017 02; 118(2):133-142.e3.
Score: 0.019
-
Gitomer SA, Fountain CR, Kingdom TT, Getz AE, Sillau SH, Katial RK, Ramakrishnan VR. Clinical Examination of Tissue Eosinophilia in Patients with Chronic Rhinosinusitis and Nasal Polyposis. Otolaryngol Head Neck Surg. 2016 07; 155(1):173-8.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|